Enclomiphene vs clomiphene vs testosterone for men: three different product paths
Enclomiphene, clomiphene, and testosterone are different product paths. The U.S. has no FDA-approved finished enclomiphene drug; clomiphene's approval is for a female ovulatory indication and male use is off label; testosterone products have product-specific approvals and labels.
Enclomiphene, clomiphene citrate, and testosterone are three different regulatory and clinical product paths. A current Drugs@FDA search identifies no FDA-approved finished enclomiphene drug; clomiphene is an FDA-approved drug for a female ovulatory indication but prescribing it to men is off label; FDA-approved testosterone products have their own labeled indications, formulations, contraindications, warnings, dosing, and monitoring. A compounded product is not FDA approved and should not be presented as a generic equivalent to an unapproved enclomiphene brand.1567
This comparison is for verifying an offer, not choosing a therapy or altering hormones.
Put every offer in the correct lane
| Offer | Regulatory starting point | Record that must follow |
|---|---|---|
| Enclomiphene capsule or tablet | No FDA-approved finished enclomiphene drug; commonly offered as a compounded preparation | Prescriber, licensed pharmacy, ingredient source, lot, formula, beyond-use date, rationale, consent, monitoring |
| Clomiphene citrate tablet | FDA-approved finished drugs exist, but male hypogonadism or fertility use is off label | Exact manufacturer and label, off-label rationale, evidence, contraindication and adverse-event review |
| Testosterone product | Multiple FDA-approved products with noninterchangeable routes and product-specific labels | Exact ester or molecule, route, strength, delivery system, indication, schedule, handling, monitoring |
| Combination membership | May include one of the above plus other prescription or compounded products | Every ingredient, indication, pharmacy, dose form, interaction, laboratory purpose, and stop owner |
Do not let “raises testosterone,” “preserves fertility,” or “TRT alternative” substitute for the finished-product identity. A physiologic goal is not a regulatory status.
The enclomiphene compounding record needs precision
FDA’s 2022 Pharmacy Compounding Advisory Committee briefing reviewed enclomiphene citrate as a bulk substance nominated for use under section 503A. FDA’s staff concluded that the evaluation criteria weighed against adding it to the 503A bulks list, and the advisory committee’s meeting record documents the discussion and vote.12
As of the September 7, 2026 review for this article, searches of FDA’s current approval database by enclomiphene name and active ingredient returned no approved finished drug.5 That is a bounded database check, not permission to infer the status of an unnamed product from a clinic’s marketing.
That history establishes several boundaries:
- nomination is not inclusion on a final list;
- an advisory vote is not a drug approval;
- bulk-substance status is not approval of a finished capsule;
- a pharmacy license is not FDA review of safety, effectiveness, or manufacturing for that finished drug; and
- an ingredient used in clinical trials is not an approved marketed product.
Ask the pharmacy and prescriber to state the current legal basis for compounding the exact preparation. A clinic screenshot from the 2022 meeting is not a current product-specific determination.
Clomiphene approval does not transfer to the male use
Clomiphene citrate includes enclomiphene and zuclomiphene isomers. FDA approval of a clomiphene product for an ovulatory indication does not mean FDA approved it for male hypogonadism, testosterone optimization, infertility, or an enclomiphene-only claim.6
Off-label prescribing of an approved drug can be lawful medical practice. The useful questions are whether the clinician established a medical problem, reviewed alternatives and evidence, documented why the off-label use is proposed, and created product-specific monitoring and adverse-event plans. “Off label” is neither a synonym for illegal nor proof of effectiveness.
Testosterone is a family of labeled products
“TRT” may mean an injection, gel, patch, nasal product, pellet, oral product, or another presentation. Exact products differ in administration, exposure, transfer risk, handling, dosing system, contraindications, warnings, and laboratory instructions; even two topical products may not have interchangeable exposure or instructions.7 Ask for the current prescribing information for the product actually proposed.
A clinic should also distinguish replacement for a diagnosed condition from a generalized anti-aging, bodybuilding, or wellness claim. One low laboratory value without appropriate timing, confirmation, symptoms, and clinical evaluation is not a complete care record. The testosterone-clinic guide lays out those verification fields.
Fertility is a separate outcome, not a slogan
Exogenous testosterone can suppress gonadotropin signaling and spermatogenesis; SERM approaches act differently.7 Recent evidence syntheses compare clomiphene or enclomiphene with placebo, testosterone gel, or other treatments and report hormonal and semen outcomes, but studies vary and long-term clinical evidence is limited.34
“Fertility preserving” therefore needs a defined baseline and endpoint. Ask:
- Is current or future biological parenthood a goal?
- Were semen analysis and reproductive history discussed before treatment?
- Which clinician owns fertility evaluation and preservation options?
- Is the cited study about hormone levels, sperm concentration, pregnancy, live birth, symptoms, or another endpoint?
- Does its population and exact product match this offer?
A laboratory rise in testosterone is not the same as symptom improvement, fertility, pregnancy, or long-term safety. Conversely, a semen measure does not answer every endocrine or sexual-health question.
Compare evidence without flattening formulations
The 2025 randomized-trial synthesis found that SERMs increased hormonal endpoints versus placebo and differed from testosterone gel in gonadotropin effects, while reporting substantial heterogeneity for some measures.3 A 2026 clomiphene-versus-testosterone synthesis found no pooled difference in its serum-testosterone change outcome and also addressed other hormonal and symptom measures across varied studies.4
Neither paper makes compounded enclomiphene FDA approved. Neither establishes that an individual should receive one product. Use them to ask better questions about population, formulation, comparator, follow-up, symptom endpoints, semen endpoints, adverse events, and study quality.
Monitoring should answer a stated question
Before treatment, document symptoms, repeat and timed laboratory rationale, relevant pituitary and reproductive evaluation, medicines and supplements, sleep and metabolic context, prostate and cardiovascular history as applicable, fertility goals, and contraindication review. The responsible clinician decides which evaluations are appropriate.
For each follow-up test, write the product, dose form, last dose timing, specimen time, assay, target question, expected action, and clinician who will interpret it. A subscription dashboard should not automatically trigger dose changes from isolated flags.
- Name the finished product. Record ingredient, isomer composition when relevant, manufacturer or compounding pharmacy, route, strength, lot, and label.
- State the regulatory status. Separate approved product, approved indication, off-label prescribing, and product-specific compounding basis.
- Define the treatment job. Document diagnosis, symptoms, fertility goals, alternatives, and which outcome would justify continuing.
- Match evidence to the offer. Compare molecule, formulation, population, comparator, hormonal and clinical endpoints, duration, and harms.
- Assign monitoring and exit care. Name the clinician for results, adverse events, fertility changes, procedures, supply interruption, and discontinuation.
The decisive question is: “What exact approved, off-label, or compounded product is this, what clinical job and evidence support it, and who owns fertility, monitoring, adverse events, and stopping?”
Sources
- U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee—Enclomiphene Citrate. FDA review used for enclomiphene identity, absence of an approved finished drug and USP monograph at review, nominated compounded uses, evidence and safety limits, and FDA's recommendation against 503A list inclusion. Accessed .
- U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, June 8, 2022. Official meeting record used to distinguish a nomination, FDA review, advisory vote, and 503A bulk-list status from finished-drug approval. Accessed .
- Archives of Endocrinology and Metabolism. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. 2025 evidence synthesis used for population, comparator, hormonal endpoints, heterogeneity, fertility measures, and limits of indirect treatment comparisons. Accessed .
- PubMed. Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis. 2026 synthesis used for the distinction between biochemical and symptom endpoints, comparative evidence, spermatogenesis considerations, and study heterogeneity. Accessed .
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Current approval database searched by active ingredient and product name to check whether an FDA-approved finished enclomiphene drug is listed as of the access date. Accessed .
- U.S. Food and Drug Administration. Clomid prescribing information. FDA-hosted labeling used for clomiphene composition, ovulatory indication, contraindications, warnings, and the absence of an approved male indication. Accessed .
- U.S. Food and Drug Administration. AndroGel 1.62% prescribing information. Current product label used as a concrete example of product-specific testosterone indications, diagnostic confirmation, route, warnings, transfer controls, spermatogenesis effects, and monitoring. Accessed .